Announcement PDF Transforming Nerve Repair Through Science ReNerve Company presentation | Quarterly webinar | August 2026 ASX:RNV ReNerve Company presentation | August 2026 Important Notice & Disclaimer 2 Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation. Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision. Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", “should”, "could", "estimates", “target”, “likely”, “plan”, "expects", "may", “intend”, "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company’s business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements. Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. More information can be obtained at the company website renerve.com.au . ReNerve Ltd ABN 23 614 848 216 ReNerve Company presentation | August 2026 ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand. Executive Summary 3 Executive Summary 3 product ranges in the US market with more coming in 2026 ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US. Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas. Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons. Development of Novel Nerve Repair & Regeneration Products Expanding Product Portfolio Strong Sales & Distribution Presence Global Expansion & Commercialisation Clinical & Professional Validation ReNerve Company presentation | August 2026 Annual revenue up 88% Executive Summary 4 Quarter highlights Revenue up >50% Compared to the previous qtr Cash of $1.48M Signed a $5M funding facility with Riverfort in early July Financial Snapshot Q4 FY26 5 Stock Price A$0.08 per share Revenue A$211K 80% increase vs corresponding quarter in FY25 Cash Position A$1.48M Capital Raised (July 2026) A$5M funding facility Riverfort facility against the R&D tax rebates Q4 FY25 Q4 FY26 Financials ReNerve Company presentation | August 2026 ReNerve Company presentation | August 2026 Executive Summary 6 Quarter highlights Distribution milestones across the NervAlign® range • Distribution partners in Hong Kong and Malaysia • Nerve Guide Matrix enters Stage 3 of 4 Stage process to FDA submission • Post quarter end – additional regional approvals in India, the Philippines & Indonesia ReNerve Company presentation | August 2026 Nerve Cuff Nerve Tube Nerve Protector Nerve Guide Matrix Nerve Cap Dermal Tissue AmnioLite AmnioDuo Placental R&D Product Development Commercial Development On Market Product Company Portfolio 7 ReNerve Company presentation | August 2026 Target Market USD$2.0Bn USD$6.0Bn Global Nerve Repair Biomaterial Market USD$1.0Bn 2025 USD$6.19Bn USD$1.90Bn USD$1.10Bn The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD$6.19Bn. 2031 Our Target Markets Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery) Dermal and Amniotic Tissue Orthopedics (Tendon and Ligament) MarketWide Research – Dermal and Amniotic tissue market report 2025- 2032, Published 2025. 8 Robust Portfolio • Expanded to 21 distributors across the US • Full logistics, warehousing and invoicing in place • Distributors can sell the entire ReNerve product range • Will add additional distributors to the network as products come to market Focus surgical areas Subspecialties • Hand (upper extremity) • Breast • Lower Extremity (M.D. & DPM) • Plastics Reconstruction • Head & Neck • Spine Sales and Marketing Update US Market Expanded Distribution Channels 9 ReNerve Company presentation | August 2026 ReNerve Company presentation | August 2026 Asia 10 • Significant opportunity • Existing distribution partner in place • Surgeon and hospital engagement already underway India • Strong local partner • Had initial orders and sales last quarter • Now engaging with the local market Hong Kong • Complements rest of Asia strategy • Will focus on key private hospital systems Philippines • Clear target customer group • Have gained initial hospital approvals • Use as a regional distribution hub Malaysia • Have initiated surgeon engagement • In discussion with local distribution partners • Focus on private hospital systems • Strong initial interest Indonesia • Focus on private hospitals • Looking to partner with local distributors Thailand RN-SM-TRN-012 Rev.0 Wound Care Overview and Information Nerve Cuff Key Features ReNerve’s “Align” Clinical Study Definitive clinical study on using NervAlign Nerve Cuff for nerve repair 120 patients per cohort; > 90 patients enrolled Comparing standard of care vs treatment with NervAlign Nerve Cuff Clinical Use • Hundreds of patients implanted to date • Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes. • Positive surgeon feedback when used with attachment methods including sutures, glue, micro clips and ‘nothing’. Product • Bio-absorbed within six months. • Produced using a non-toxic method. • Terminally sterilised with no residual chemicals. • Covered under procedural reimbursement rather than individual product reimbursement. • Promotes revascularisation and remodelling. • Semi-translucent Patient Benefit ● Requires no change to surgical technique or procedures. ● Available in various sizes with ability to be trimmed to required shape. ● Pliable, conformable, semi-translucent and easy to use. Surgeon Benefit 3 2 1 Patient Results • Protects nerves during recovery post peripheral nerve repair • Great handling characteristics and absorbed within 6 months 12 ReNerve Company presentation | August 2026 The “Align” Study Clinical Study on the NervAlign® Nerve Cuff Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve repair surgery. Study Design: Two patient cohorts • Control Group: Standard neurectomy repair • Test Group: Neurectomy repair with NervAlign Nerve Cuff • Based on the study which showed clear benefit for using the NervAlign Nerve Cuff Key Outcomes: • Testing for significance in Pain Reduction: ‒ Secondary outcomes in patient recovery ‒ Product performance in surgery • Patient follow-up around 6 to 9 months Data presentation • Aiming to complete recruitment by mid 2026 • Data accumulated along the way • First 50 patients recruited to date • Data likely to be published and presented in late 2026/early 2027 Comparison of Patient Pre & Post Surgery Pain Score Standard of Care NervAlign Nerve Cuff Protected The comparison of pain scores between the two cohorts of patients 54% Improvement 96% Improvement 7.1 7.1 3.3 0.4 13 ReNerve Company presentation | August 2026 RN-SM-TRN-012 Rev.0 Wound Care Overview and Information Product Development Pipeline Product Development Pipeline Nerve conduit range Nerve Conduit and protector ranges ● Entering validation commercial production this quarter ● 3 types of conduits to come to market Nerve guide matrix In commercial development Stage 3 of 4 FDA approval pathway confirmed 12-month preclinical implant data due this quarter 15 ReNerve Company presentation | August 2026 RN-SM-TRN-012 Rev.0 Wound Care Overview and Information Product Range ReNerve Company presentation | August 2026 17 Empliq Product Portfolio Empliq AmnioLite Empliq AmnioDuo Empliq Placental Empliq Dermal Description Single-layer amniotic membrane allograft Double-layer amniotic membrane allograft Placental allograft including amniotic membrane and chorion Deep-layer dermal matrix Clinical Value Natural barrier to protect wounds from external environment Thicker barrier for complex wounds Improved handling characteristics Natural barrier to protect wounds from external environment Additional structural support Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing Potential Applications DFUs, VLUs, surgical wounds, vulnerable tissue DFUs, VLUs, pressure injury, surgical wounds Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair ReNerve Company presentation | August 2026 Executive Summary 18 Catalysts CY26 Continued focus on sales expansion as first direct sales reps starting to impact revenue growth NervAlign® Nerve Cuff launches and sales across India and Asia Complete recruitment of the “Align” study in peripheral nerve repairs European approval submission, utilising the data from the 'Align' study Market launch of the 1st NervAlign® Nerve Conduit 12-month data for preclinical implants of the NervAlign® Nerve Guide Matrix Growth of the Empliq brand Value drivers for the next 12 months Driving sales and new products into market ● Complements the nerve products sales ● Anticipating faster sales growth through multiple products ● Additional supply partners to ensure product availability as sales grow Empliq products ranges now in the US market ● Direct sales team in the US having an impact on sales growth ● Increasing hospital approvals, now over 100 ● Rising sales with multiple product ranges in market Working with distributors for additional approvals ● Strong, positive data in 2025 ● The “Align” study exploring the benefit of NervAlign in nerve repair ● The “Align” study 80% recruited ● Initial data due in 2026 Ongoing Clinical Study ● Establishing partners Ex-USA ● Initial product launches across India and Asia ● Follow on with new products, the first being the nerve conduit Continue to expand into Ex-US markets 2026 focus on major commercial progress 19 ReNerve Company presentation | August 2026 Investment Highlights In Market Products Immediate Market Need Growing Market Diverse Product Portfolio Growing Distribution Board & Management Nerve Cuff transitioned from R&D to commercial sales with 3 product lines in market and nerve conduits coming. Products promote nerve injury recovery and wound repair leading to faster patient recovery and better outcomes. Nerve repair biomaterials & related markets are forecast to grow by >17% pa, estimated to be worth >US$6.19Bn by 2031. USD$1Bn+ market for human tissue product ranges. Building a complete product range in market with 3 in market and more coming in 2026. Additional products currently under development. Continuing to build sales representation with a targeted direct- sales approach. Expanding globally. Highly accomplished executive team with a proven track record in the development & commercialisation of medical opportunities. 20 ReNerve Company presentation | August 2026 Contact Us ReNerve Limited info@renerve.com.au Level 10/99 Queen St, Melbourne, Victoria 3000 Australia +61 (03) 9482 3940 Follow us on socials! ReNerve Company presentation | August 2026 Product • Used on damaged or transected nerves with no gaps or gap closure • Improved Nerve Cuff developed from scCO2 tissue, offering better product profile • An ‘off-the-shelf’, ready to use nerve graft replacement with internal guidance infrastructure • An ‘off-the-shelf’, continuous nerve replacement, in a ready to use nerve structure Procedure Use • End to end suturing covered with a wrap/cuff • Protective cuff for grafts • Protecting injured nerve repairs • Replaces damaged nerve section instead of using donor or harvested tissue • The Bionic Nerve is a nerve guide matrix with ionic polymers designed to replace injured and damaged nerves for lengths from 1cm to 20cm Application • Trauma • Breast reconstruction • Orthopaedics • Oral & maxillofacial surgery • Trauma • Breast reconstruction • Orthopaedics • Foot and ankle • Trauma • Breast reconstruction • Orthopaedics • Hand & wrist • Trauma • Craniotomy • Spinal cord injury • Spinal cord surgery Benefit • Bio-absorbed removing need for additional surgery • Pliable and conforms • Improved product profile to Nerve Cuff • Stronger patient reimbursement • Can be cut to ideal length • Off-the-shelf, reducing logistics issues • Simple to use and cost effective • Enable production of nerves of bespoke dimension FDA Status Approved Targeting market release CY26 Targeting Q2 CY27 filing Targeting Q3 CY28 filing TAM (USD) $314m $975m 2024 2030 $635m $1991m 2024 2030 $1015m $3219m 2024 2030 >$400m 2023 Nerve Cuff Bionic Nerve Nerve Conduit Nerve Guide Matrix ReNerve’s Nerve Opportunity 22